Evidence map›Paper›PMID 33303833›Full record

ArticleScientific reports2020

Comparison of the amniotic fluid and fetal urine peptidome for biomarker discovery in renal developmental disease.

Camille Fédou, Benjamin Breuil, Igor Golovko, Stéphane Decramer, Pedro Magalhães, Françoise Muller, Sophie Dreux, Petra Zürbig, Julie Klein, Joost P Schanstra and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Prenatal body fluid analysis in the evaluation of CAKUT.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Camille FédouInstitut National de La Santé Et de La Recherche Médicale (INSERM), U1048/I2MC-Equipe 12, Institut of Cardiovascular and Metabolic Disease, 1 Avenue Jean Poulhès, BP 84225, 31432, Toulouse Cedex 4, France.
Benjamin BreuilInstitut National de La Santé Et de La Recherche Médicale (INSERM), U1048/I2MC-Equipe 12, Institut of Cardiovascular and Metabolic Disease, 1 Avenue Jean Poulhès, BP 84225, 31432, Toulouse Cedex 4, France.
Igor GolovkoMosaiques Diagnostics GmbH, Hannover, Germany.
Stéphane DecramerInstitut National de La Santé Et de La Recherche Médicale (INSERM), U1048/I2MC-Equipe 12, Institut of Cardiovascular and Metabolic Disease, 1 Avenue Jean Poulhès, BP 84225, 31432, Toulouse Cedex 4, France.
Pedro MagalhãesMosaiques Diagnostics GmbH, Hannover, Germany.
Françoise MullerUnité de Biochimie Fœto-Placentaire, Laboratoire de Biochimie - Hormonologie CHU Robert Debré, AP-HP, Paris, France.
Sophie DreuxUnité de Biochimie Fœto-Placentaire, Laboratoire de Biochimie - Hormonologie CHU Robert Debré, AP-HP, Paris, France.
Petra ZürbigMosaiques Diagnostics GmbH, Hannover, Germany.
Julie KleinInstitut National de La Santé Et de La Recherche Médicale (INSERM), U1048/I2MC-Equipe 12, Institut of Cardiovascular and Metabolic Disease, 1 Avenue Jean Poulhès, BP 84225, 31432, Toulouse Cedex 4, France.
Joost P SchanstraInstitut National de La Santé Et de La Recherche Médicale (INSERM), U1048/I2MC-Equipe 12, Institut of Cardiovascular and Metabolic Disease, 1 Avenue Jean Poulhès, BP 84225, 31432, Toulouse Cedex 4, France. joost-peter.schanstra@inserm.fr.
Bénédicte Buffin-MeyerInstitut National de La Santé Et de La Recherche Médicale (INSERM), U1048/I2MC-Equipe 12, Institut of Cardiovascular and Metabolic Disease, 1 Avenue Jean Poulhès, BP 84225, 31432, Toulouse Cedex 4, France. benedicte.buffin-meyer@inserm.fr.
Inserm · FRMosaiques Diagnostics and Therapeutics (Germany) · DEAssistance Publique – Hôpitaux de Paris · FRInstitut des Maladies Métaboliques et Cardiovasculaires · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Production of amniotic fluid (AF) is view as predominately driven by excretion of fetal urine (FU). However, the origin of AF peptides, often considered as potential biomarkers of developmental diseases, has never been investigated. Here, we evaluated the FU origin of AF peptides and if the AF peptide content can be used as a surrogate of FU. The abundance of endogenous peptides was analyzed by capillary electrophoresis coupled to mass spectrometry in 216 AF and 64 FU samples. A total of 2668 and 3257 peptides was found in AF and FU respectively. The AF peptidome largely overlapped with the FU peptidome, ranging from 54% in the second pregnancy trimester to 65% in the third trimester. Examination of a subset of 16 paired AF and FU samples revealed that 67 peptides displayed a significant positively correlated abundance in AF and FU, strongly suggesting that their presence in AF was directly associated to FU excretion. As proof-of-concept we showed that measuring the AF abundance of these 67 peptides of FU origin allowed prediction of postnatal renal survival in fetuses with posterior urethral valves. These results demonstrate that the AF peptidome can be considered as a good surrogate of the FU peptidome.

Indexed as

Amniotic FluidBiomarkersFemaleGestational AgeHumansKidney DiseasesPeptidesPregnancyPregnancy Trimester, SecondRetrospective StudiesBiomarkersPeptides

Identifiers

PMID33303833
PMCPMC7729974
OpenAlexW3112647075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.